Docosahexaenoic Acid
Urologic Diseases
University of CatanzaroSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Urologic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rocuronium Rainer Lenhardt | Phase 4 | BB |
NKT2152 NiKang Therapeutics, Inc. | Phase 2 | CCC |
Palbociclib NiKang Therapeutics, Inc. | Phase 2 | CCC |
Tranexamic Acid Fraser Health | Phase 1/2 | CCC |
Atezolizumab Celldex Therapeutics | Phase 1 | CC |
View all 12 →
Same molecule, other indications
Docosahexaenoic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →